South Korean Drug for Lung Cancer Gains FDA Approval, Marking Industry Milestone

  Yuhan’s Leclaza (lazertinib) (Image provided by Yuhan Corporation) SEOUL, Aug. 23 (Korea Bizwire) – In a significant breakthrough for South Korea’s pharmaceutical industry, Yuhan Corporation’s non-small cell lung cancer treatment has cleared a crucial hurdle with the U.S. Food and Drug Administration (FDA). On August 20, the FDA approved the combination therapy of Yuhan’s [...]